CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection.

Published

Journal Article

Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.

Full Text

Duke Authors

Cited Authors

  • Kwa, S; Sadagopal, S; Shen, X; Hong, JJ; Gangadhara, S; Basu, R; Victor, B; Iyer, SS; LaBranche, CC; Montefiori, DC; Tomaras, GD; Villinger, F; Moss, B; Kozlowski, PA; Amara, RR

Published Date

  • April 2015

Published In

Volume / Issue

  • 89 / 8

Start / End Page

  • 4690 - 4695

PubMed ID

  • 25653428

Pubmed Central ID

  • 25653428

Electronic International Standard Serial Number (EISSN)

  • 1098-5514

Digital Object Identifier (DOI)

  • 10.1128/JVI.03527-14

Language

  • eng

Conference Location

  • United States